gip glp 1 agonist tirzepatide Semaglutide vs Research Comparison GLP-1 receptor agonists are increasingly

Mieszawska, A

doi: 10.1016/j.lfs.2017.08.006

Potential Impact on Sales of Fast Food and Convenience Foods Many fast-food chains and convenience food producers may see decreased sales if a significant portion of consumers on GLP-1 drugs reduce their frequency of fast-food meals

This includes comparing the affected side with the unaffected one to detect any asymmetries

At the same time, Novo Nordisk and Eli Lilly are expanding their captive peptide API manufacturing capabilities to complement outsourced production, enhance supply-chain resilience, and meet the rapidly growing global demand for semaglutide- and tirzepatide-based products